Journals / Molecular Imaging and Radionuclide Therapy / 2016 / Cilt: 25 - Sayı: 2

Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up

Diferansiye Tiroit Karsinomunda Rekürrens Sıklığı ve Klinik İzlemde Tanısal İyot-131 Sintigrafisinin Önemi

Pages
85–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Identification of pathological findings with WBS in patients who developed local recurrence in the absence of elevated Tg highlights the importance of diagnostic WBS in clinical follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Differentiated thyroid cancers (DTC) are tumors with good prognosis.
📊
Key Findings & Data:In our study, we aimed to investigate the incidence of recurrence and the importance of diagnostic iodine-131 whole body scan (WBS) in clinical follow-up in patients with DTC.
💡
Conclusion & Impact:Conclusion: Identification of pathological findings with WBS in patients who developed local recurrence in the absence of elevated Tg highlights the importance of diagnostic WBS in clinical follow-up.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Differentiated thyroid cancers (DTC) are tumors with good prognosis. However, local recurrence or distant metastasis can be observed. In our study, we aimed to investigate the incidence of recurrence and the importance of diagnostic iodine-131 whole body scan (WBS) in clinical follow-up in patients with DTC. Methods: The clinical data of 217 patients with DTC who were followed-up more than 3 years were reviewed retrospectively. The incidence of recurrence was investigated in a group of patients who had radioactive iodine (RAI) treatment and showed no sign of residual thyroid tissue or metastasis with diagnostic WBS that was performed at 6-12 months after therapy and had a thyroglobulin (Tg) level lower than 2 ng/dl. Results: At the time of diagnosis, ten cases had thyroid capsule invasion, 25 cases had extra-thyroid soft tissue invasion, 11 patients showed lymph node metastasis and four patients had distant organ metastasis. One hundred forty-five patients had RAI treatment at ablation dose (75-100 mCi), whereas 35 patients had RAI treatment at metastasis dose (150-200 mCi). Thirty-seven patients with papillary microcarcinoma did not receive RAI treatment. In 12 (%7.5) of the 160 patients who were considered as "successful ablation", a recurrence was identified. Recurrence was detected by diagnostic WBS in all cases and stimulated Tg level was <2 ng/dL with the exception of the two cases who had distant metastasis. Conclusion: Identification of pathological findings with WBS in patients who developed local recurrence in the absence of elevated Tg highlights the importance of diagnostic WBS in clinical follow-up.

Özet

Amaç: Diferansiye tiroit karsinomları (DTK) iyi prognoza sahip tümörlerdir. Ancak lokal rekürrens ve uzak metastaz izlenebilmektedir. Çalışmamızda DTK'lı olgularda rekürrens sıklığının ve tanısal iyot-131 (I-131) tüm vücut tarama sintigrafisinin klinik izlemdeki öneminin araştırılması amaçlandı.Yöntem: İzlem süresi 3 yılın üzerinde olan iki yüz on yedi DTK'lı olgunun klinik verileri retrospektif olarak incelendi. Radyoiyot (RAI) tedavisi alan hastalardan tedavi sonrası 6. ay-1. yıl tanısal I-131 tarama sintigrafisinde rezidüel tiroit dokusu ve metastaza ait bulgu saptanmayan, tiroglobulin (Tg) düzeyi 2 ng/dl'nin altında olan grupta rekürrens sıklığı araştırıldı. Bulgular: Tanı anında on olguda tiroit kapsülü, 25 olguda ekstratiroidal yumuşak doku invazyonu, 11 hastada lenf nodu metastazı ve dört hastada uzak metastaz mevcuttu. Yüz kırk beş olgu ablasyon dozunda (75-100 mCi), 35 olgu metastaz dozunda (150-200 mCi) RAI tedavisi almıştı. Papiller mikrokarsinom tanılı 37 hasta ise RAI tedavisi almamıştı. Tedavi başarısına karar verilen 160 hastanın 12'sinde rekürren hastalık saptandı (%7,5). Olguların tümünde rekürrens I-131 tarama sintigrafisi ile saptanmış olup uzak metastazı olan iki hasta dışında stimüle Tg değerleri <2 ng/dL idi. Sonuç: Lokal rekürrens gelişen tüm olgularda stimüle Tg yüksekliği olmaksızın I-131 tarama sintigrafisi ile patolojik bulguların saptanması klinik izlemde tanısal I-131 taramanın önemini vurgulamaktadır.

🔖

Cite This Article

HATİPOĞLU, F., KARAPOLAT, İ., ÖMÜR, Ö., AKGÜN, A., YANARATEŞ, A., KUMANLIOĞLU, K. (2016). Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up. Molecular Imaging and Radionuclide Therapy, Cilt: 25 - Sayı: 2, 85–90. https://ajindex.com/articles/295142

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini L. Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 2009;20:1728-1735
  2. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110:1451-1456
  3. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87. 4. de Meer SG, Vriens MR, Zelissen PM, Rinkes IHB, de Keizer B. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. J Nucl Med 2011;52:56- 59
  4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214
  5. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-711
  6. Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F. Comparison of positron emission tomography with (F18) FDG and (68)Ga DOTATOC in recurrent differantiated thyroid cancer: Preliminary data. Q J Nucl Med Mol Imaging 2010;54:76-83
  7. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306
  8. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-967
  9. Gerrard GE, Mason MT. The recurrence rate for low-risk differentiated thyroid cancer is extremely low (0.5% after more than 5 years of follow-up). Clin Oncol (R Coll Radiol) 2011;23:374-375
  10. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I-131). Ann Surg 1994;219:587- 593
  11. Ito Y